Dr. Wei Bai, MD
Hematology & Oncology (Hematology & Oncology Physician)
1325 E Church St Ste 301
Santa Maria, CA 93454
Who else practices at this address →
Santa Barbara County includes primary care (2% of residents) and mental health (21% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 31
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 307
Licensed in California since 2019, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
CA license C166101 (first issued 2019; current) · OR license MD153848
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Marian Regional Medical Center Santa Maria, CA
Medical groups
- Pacific Central Coast Health Centers (253 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 307
- Services billed
- 1,216
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 817 | 213 |
| Established patient office or other outpatient visit, 20-29 minutes | 178 | 125 |
| Established patient office or other outpatient visit, 40-54 minutes | 171 | 81 |
| New patient office or other outpatient visit, 60-74 minutes | 37 | 37 |
| New patient office or other outpatient visit, 45-59 minutes | 29 | 29 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 18 | 17 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Letrozole Other prescribers in Santa Maria, CA | 106 |
| Anastrozole Other prescribers in Santa Maria, CA | 64 |
| Hydroxyurea Other prescribers in Santa Maria, CA | 50 |
| Xarelto (rivaroxaban) Other prescribers in Santa Maria, CA | 34 |
| Alendronate Sodium Other prescribers in Santa Maria, CA | 29 |
| Verzenio (abemaciclib) | 21 |
| Eliquis (apixaban) Other prescribers in Santa Maria, CA | 21 |
| Potassium Chloride Other prescribers in Santa Maria, CA | 20 |
| Prednisone Other prescribers in Santa Maria, CA | 19 |
| Tagrisso (osimertinib mesylate) | 18 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 13 companies reported 26 payments worth $8,225 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $6,741 |
|---|---|
| Incyte Corporation | $1,100 |
| Exelixis Inc. | $96.90 |
| Atricure, Inc. | $78.04 |
| Array Biopharma Inc | $39.39 |
| Gilead Sciences, Inc. | $32.41 |
| Astellas Pharma US Inc | $28.93 |
| Genmab U.S., Inc. | $22.03 |
| Consulting Fee | $7,425 |
|---|---|
| Food and Beverage | $477 |
| Travel and Lodging | $323 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP Oct 28, 2025 | Consulting Fee | $2,200 |
| AstraZeneca Pharmaceuticals LP Nov 4, 2025 | Consulting Fee TAGRISSO · Oncology | $1,650 |
| AstraZeneca Pharmaceuticals LP Nov 3, 2025 | Consulting Fee IMFINZI · Oncology | $1,375 |
| Incyte Corporation Apr 28, 2025 | Consulting Fee | $1,100 |
| AstraZeneca Pharmaceuticals LP Jun 3, 2025 | Consulting Fee IMFINZI · Oncology | $1,100 |
| AstraZeneca Pharmaceuticals LP Oct 24, 2025 | Travel and Lodging travel to Denver, CO · in-kind Company’s descriptionConsulting Expenses | $323 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $38,101 in research payments for these studies, mostly to the institutions running them.
- Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia
Beone Medicines USA, Inc. · Recruiting · NCT05640102 - Cold Agglutinin Disease Real World Evidence Registry
Sanofi US Services Inc. · Active, not recruiting · NCT05791708
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.